Formycon AG
XETRA:FYB

Watchlist Manager
Formycon AG Logo
Formycon AG
XETRA:FYB
Watchlist
Price: 46.85 EUR 0.75% Market Closed
Market Cap: 827.6m EUR
Have any thoughts about
Formycon AG?
Write Note

Formycon AG
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Formycon AG
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Formycon AG
XETRA:FYB
Intangible Assets
€508.4m
CAGR 3-Years
1 133%
CAGR 5-Years
392%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Intangible Assets
€804.1m
CAGR 3-Years
94%
CAGR 5-Years
56%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Intangible Assets
€786.3m
CAGR 3-Years
125%
CAGR 5-Years
79%
CAGR 10-Years
40%
CureVac NV
NASDAQ:CVAC
Intangible Assets
€15.9m
CAGR 3-Years
4%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Intangible Assets
€1.5m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Intangible Assets
€16.4m
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
-10%
No Stocks Found

Formycon AG
Glance View

Market Cap
827.2m EUR
Industry
Biotechnology

Formycon AG engages in the manufacture of biosimilar drugs and formulations. The company is headquartered in Martinsried, Bayern and currently employs 159 full-time employees. The company went IPO on 2010-12-20. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The firm focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

FYB Intrinsic Value
95.53 EUR
Undervaluation 51%
Intrinsic Value
Price

See Also

What is Formycon AG's Intangible Assets?
Intangible Assets
508.4m EUR

Based on the financial report for Dec 31, 2023, Formycon AG's Intangible Assets amounts to 508.4m EUR.

What is Formycon AG's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
392%

Over the last year, the Intangible Assets growth was 4%. The average annual Intangible Assets growth rates for Formycon AG have been 1 133% over the past three years , 392% over the past five years .

Back to Top